Digital ILC 2020 session: NAFLD - Target identification and drug pipeline
Digital ILC 2020 abstract session: NAFLD - Experimental
Digital ILC 2020 - Immunity & HCC abstract session
Digital ILC 2020. Immune-mediated and chronic cholestatic liver disease - Clinical aspects.
Digital ILC 2020 General Session 1
Cirrhosis and Complications Digital ILC 2020
Digital ILC 2020:Immune-mediated & chronic cholestasic liver disease: Experimental & pathophysiology
Digital ILC 2020: General session II
NAFLD Pharmacological therapy abstract session
Viral hepatitis abstract session at Digital ILC 2020
Digital ILC 2020 - General hepatology: Late-breakers abstracts session
Abstract session Liver fibrosis
Digital ILC 2020 session: From liver transplantation to systemic therapy in Hepatocellular Carcinoma
Welcome to the Digital ILC 2020
Digital International Liver Congress 2020
Explore EASL Campus
EASL Digital ILC 2020 Wrap-Up: A Complicated Picture Emerges - Ep 24
NAFLD Summit Program -5th July 2020
EASL Policy Statement on the coexistence of NAFLD and ARLD (Patient Forum 2020)
S2-E31.2 - Previewing Digital ILC 2021 -- Part II -- Drug Development
EASL Studio Midday Talks: Steatotic liver disease global consensus to change nomenclature
EASL Studio S4E12 - NAFLD and NASH – moving beyond the liver biopsy – where are we now?
"Liver pancreas cross talk in the context of NAFLD"
Dr. Quentin Anstee
FLF LIVER Webinar Series | Part-One (Highlights from EASL 2020)